lifestyle.harcourthealth.com

JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025

Written by

businesswire

JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025 – NEWSnet – News… as it used to be


More Press Releases